To date, the JAK2 inhibitor ruxolitinib is approved only for palliation of symptoms associated with splenomegaly and fatigue,3 and there is no evidence that JAK2 inhibitors can reverse MF. This evidence concerns the gene JAK2 and Splenomegaly.